## Marisa B Marques

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5597205/publications.pdf

Version: 2024-02-01

109321 76900 6,062 150 35 74 citations g-index h-index papers 152 152 152 7129 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Red Blood Cell Transfusion: A Clinical Practice Guideline From the AABB*. Annals of Internal Medicine, 2012, 157, 49.	3.9	920
2	Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. Journal of Clinical Investigation, 2012, 122, 2661-2671.	8.2	838
3	Guidelines on the use of therapeutic apheresis in clinical practice—Evidenceâ€based approach from the apheresis applications committee of the American Society for Apheresis. Journal of Clinical Apheresis, 2010, 25, 83-177.	1.3	441
4	Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematology, the, 2017, 4, e157-e164.	4.6	338
5	Guidelines on the use of therapeutic apheresis in clinical practice—Evidenceâ€based approach from the apheresis applications committee of the American society for apheresis. Journal of Clinical Apheresis, 2007, 22, 106-175.	1.3	308
6	Age of Transfused Blood: An Independent Predictor of Mortality Despite Universal Leukoreduction. Journal of Trauma, 2008, 65, 279-284.	2.3	170
7	Transfusions in the Less Severely Injured: Does Age of Transfused Blood Affect Outcomes?. Journal of Trauma, 2008, 65, 794-798.	2.3	125
8	Duration of Red Cell Storage Influences Mortality After Trauma. Journal of Trauma, 2010, 69, 1427-1432.	2.3	111
9	Acute transient leukopenia as a sign of TRALI. American Journal of Hematology, 2005, 80, 90-91.	4.1	99
10	Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research. Journal of Clinical Apheresis, 2014, 29, 148-167.	1.3	99
11	Metabolic Plasticity in Resting and Thrombin Activated Platelets. PLoS ONE, 2015, 10, e0123597.	2.5	98
12	Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin. American Journal of Hematology, 2006, 81, 199-201.	4.1	96
13	Making thawed universal donor plasma available rapidly for massively bleeding trauma patients: experience from the Pragmatic, Randomized Optimal Platelets and Plasma Ratios (PROPPR) trial. Transfusion, 2015, 55, 1331-1339.	1.6	73
14	Educating Medical Students in Laboratory Medicine. American Journal of Clinical Pathology, 2010, 133, 533-542.	0.7	71
15	The success of our patient blood management program depended on an institutionâ€wide change in transfusion practices. Transfusion, 2014, 54, 2617-2624.	1.6	61
16	Erythrocyte storage increases rates of NO and nitrite scavenging: implications for transfusion-related toxicity. Biochemical Journal, 2012, 446, 499-508.	3.7	59
17	The Yield of Bone Marrow Biopsy and Culture Compared with Blood Culture in the Evaluation of HIV-infected Patients for Mycobacterial and Fungal Infections. American Journal of Medicine, 1998, 104, 123-128.	1.5	55
18	Transfusion-Related Acute Lung Injury. American Journal of Clinical Pathology, 2008, 129, 287-297.	0.7	55

#	Article	IF	CITATIONS
19	Absorbance and redox based approaches for measuring free heme and free hemoglobin in biological matrices. Redox Biology, 2016, 9, 167-177.	9.0	55
20	Influence of Kidney Function on Risk of Supratherapeutic International Normalized Ratio–Related Hemorrhage in Warfarin Users: A Prospective Cohort Study. American Journal of Kidney Diseases, 2015, 65, 701-709.	1.9	52
21	Peroxiredoxin-2 Recycling Is Inhibited During Erythrocyte Storage. Antioxidants and Redox Signaling, 2015, 22, 294-307.	5.4	52
22	Clinical factors and biomarkers predict outcome in patients with immune-mediated thrombotic thrombocytopenic purpura. Haematologica, 2019, 104, 166-175.	3.5	52
23	Role of heme in lung bacterial infection after trauma hemorrhage and stored red blood cell transfusion: A preclinical experimental study. PLoS Medicine, 2018, 15, e1002522.	8.4	51
24	Is therapeutic plasma exchange indicated for patients with gemcitabineâ€induced hemolytic uremic syndrome?. Journal of Clinical Apheresis, 2009, 24, 209-214.	1.3	50
25	Transfusion and Pneumonia in the Trauma Intensive Care Unit: An Examination of the Temporal Relationship. Journal of Trauma, 2009, 67, 97-101.	2.3	49
26	Recommendations for Appropriate Activated Partial Thromboplastin Time Reagent Selection and Utilization. American Journal of Clinical Pathology, 2012, 137, 904-908.	0.7	47
27	Patient Blood Management as Standard of Care. Anesthesia and Analgesia, 2016, 123, 1051-1053.	2.2	44
28	Photopheresis in solid organ transplant rejection. Journal of Clinical Apheresis, 2006, 21, 72-77.	1.3	43
29	Thrombelastographic measures of clot propagation: a comparison of alpha with the maximum rate of thrombus generation. Blood Coagulation and Fibrinolysis, 2007, 18, 45-48.	1.0	42
30	Adverse Effects of Transfusion. Cancer Control, 2015, 22, 16-25.	1.8	42
31	Red blood cell washing, nitrite therapy, and antiheme therapies prevent stored red blood cell toxicity after trauma–hemorrhage. Free Radical Biology and Medicine, 2015, 85, 207-218.	2.9	42
32	Three neglected numbers in the CBC: The RDW, MPV, and NRBC count. Cleveland Clinic Journal of Medicine, 2019, 86, 167-172.	1.3	42
33	Platelet Count and Prothrombin Time Help Distinguish Thrombotic Thrombocytopenic Purpura–Hemolytic Uremic Syndrome From Disseminated Intravascular Coagulation in Adults. American Journal of Clinical Pathology, 2010, 133, 460-465.	0.7	40
34	Update on extracorporeal photopheresis in heart and lung transplantation. Journal of Clinical Apheresis, 2011, 26, 146-151.	1.3	39
35	Older Blood Is Associated With Increased Mortality and Adverse Events in Massively Transfused Trauma Patients: Secondary Analysis of the PROPPR Trial. Annals of Emergency Medicine, 2019, 73, 650-661.	0.6	38
36	Vascular access for therapeutic plasma exchange. Transfusion, 2018, 58, 580-589.	1.6	37

#	Article	IF	CITATIONS
37	Pathology Consultation on the Diagnosis and Treatment of Thrombotic Microangiopathies (TMAs). American Journal of Clinical Pathology, 2016, 145, 158-165.	0.7	34
38	Characterization of Storage-Induced Red Blood Cell Hemolysis Using Raman Spectroscopy. Laboratory Medicine, 2018, 49, 298-310.	1.2	34
39	Predictors of response and relapse in a cohort of adults with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: a single-institution experience. Transfusion, 2007, 47, 107-114.	1.6	33
40	Continuous infusion of calcium gluconate in 5% albumin is safe and prevents most hypocalcemic reactions during therapeutic plasma exchange. Journal of Clinical Apheresis, 2007, 22, 265-269.	1.3	31
41	Perceptions About Blood Transfusion. Anesthesia and Analgesia, 2014, 118, 1301-1308.	2.2	30
42	Management of a patient with HIV infection-induced anemia and thrombocytopenia who presented with thrombotic thrombocytopenic purpura. American Journal of Hematology, 2002, 69, 228-231.	4.1	29
43	Estimating blood needs for very-low-birth-weight infants. Transfusion, 2006, 46, 1915-1920.	1.6	28
44	Extracorporeal photopheresis practice patterns: An international survey by the ASFA ECP subcommittee. Journal of Clinical Apheresis, 2017, 32, 215-223.	1.3	27
45	Unusual Thromboses Associated with Protein S Deficiency in Patients with Acquired Immunodeficiency Syndrome: Case Reports and Review of the Literature. AIDS Research and Human Retroviruses, 2005, 21, 753-756.	1.1	26
46	Category IV indications for therapeutic apheresis—ASFA fourth special issue. Journal of Clinical Apheresis, 2007, 22, 176-180.	1.3	26
47	The Clinical Pathologist as Consultant. American Journal of Clinical Pathology, 2011, 135, 11-12.	0.7	26
48	Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency. Cell Reports Medicine, 2021, 2, 100164.	6.5	26
49	Phase II study of docetaxel plus enoxaparin in chemotherapy-naive patients with metastatic non-small cell lung cancer: preliminary results. Lung Cancer, 2003, 42, 237-245.	2.0	25
50	Longitudinal assessments of plasma ADAMTS13 biomarkers predict recurrence of immune thrombotic thrombocytopenic purpura. Blood Advances, 2019, 3, 4177-4186.	<b>5.</b> 2	25
51	First symptoms in patients with thrombotic thrombocytopenic purpura: what are they and when do they occur?. Transfusion, 2013, 53, 235-237.	1.6	24
52	Single-center experience with extracorporeal photopheresis in pediatric heart transplantation. Journal of Heart and Lung Transplantation, 2014, 33, 624-628.	0.6	23
53	Defining the effects of storage on platelet bioenergetics: The role of increased proton leak. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 2525-2534.	3.8	23
54	Patients with thrombotic thrombocytopenic purpura commonly develop metabolic alkalosis during therapeutic plasma exchange. Journal of Clinical Apheresis, 2001, 16, 120-124.	1.3	22

#	Article	IF	CITATIONS
55	High Percentage of Evanescent Red Cell Antibodies in Patients with Sickle Cell Disease Highlights Need for a National Antibody Database. Southern Medical Journal, 2016, 109, 588-591.	0.7	22
56	Clinical Scoring Systems in Thrombotic Microangiopathies. Seminars in Thrombosis and Hemostasis, 2017, 43, 540-548.	2.7	21
57	Multiorgan failure and bone marrow necrosis in three adults with sickle cellâ€Î² <sup>+</sup> â€thalassemia. American Journal of Hematology, 2012, 87, 621-624.	4.1	20
58	Revisiting fat embolism in sickle syndromes: diagnostic and emergency therapeutic measures. British Journal of Haematology, 2019, 186, e112-e115.	2.5	20
59	Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpura. Haematologica, 2016, 101, 1319-1326.	3.5	19
60	Fat Embolism Syndrome Secondary to Bone Marrow Necrosis in Patients with Hemoglobinopathies. Southern Medical Journal, 2016, 109, 549-553.	0.7	19
61	The isolated prolonged PTT. American Journal of Hematology, 2013, 88, 82-85.	4.1	18
62	Extracorporeal photopheresis: Technique, established and novel indications. Journal of Clinical Apheresis, 2014, 29, 228-234.	1.3	18
63	Increased troponin I is associated with fatal outcome in acquired thrombotic thrombocytopenic purpura. Journal of Clinical Apheresis, 2017, 32, 311-318.	1.3	18
64	Characteristics of photopheresis treatments for the management of rejection in heart and lung transplant recipients. Journal of Clinical Apheresis, 2002, 17, 27-32.	1.3	17
65	Thrombotic Thrombocytopenic Purpura and Heparin-Induced Thrombocytopenia: Two Unique Causes of Life-Threatening Thrombocytopenia. Clinics in Laboratory Medicine, 2009, 29, 321-338.	1.4	17
66	Predicting storageâ€dependent damage to red blood cells using nitrite oxidation kinetics, peroxiredoxinâ€2 oxidation, and hemoglobin and free heme measurements. Transfusion, 2015, 55, 2967-2978.	1.6	17
67	Plasma levels of S100A8/A9, histone/DNA complexes, and cellâ€free DNA predict adverse outcomes of immune thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2021, 19, 370-379.	3.8	17
68	How we closed the gap between red blood cell utilization and whole blood collections in our institution. Transfusion, 2012, 52, 1857-1867.	1.6	16
69	Relapses of thrombotic thrombocytopenic purpura after treatment with rituximab. Journal of Clinical Apheresis, 2013, 28, 390-394.	1.3	16
70	Compliance rates and outcomes associated with a restrictive transfusion policy in gynecologic oncology patients. Gynecologic Oncology, 2014, 132, 227-230.	1.4	16
71	Free flap failure secondary to dual thrombophilia. Microsurgery, 2009, 29, 62-65.	1.3	15
72	Zika Virus and Patient Blood Management. Anesthesia and Analgesia, 2017, 124, 282-289.	2.2	15

#	Article	IF	CITATIONS
73	Anti-Rh alloimmunization after trauma resuscitation. Transfusion and Apheresis Science, 2019, 58, 102652.	1.0	14
74	Pathology Consultation on the Laboratory Evaluation of Thrombophilia. American Journal of Clinical Pathology, 2012, 137, 553-560.	0.7	13
75	Decoding Laboratory Test Names: A Major Challenge to Appropriate Patient Care. Journal of General Internal Medicine, 2013, 28, 453-458.	2.6	13
76	Modification of platelet proteins by 4-hydroxynonenal: Potential Mechanisms for inhibition of aggregation and metabolism. Free Radical Biology and Medicine, 2016, 91, 143-153.	2.9	13
77	Management of chronic myeloid leukemia in the setting of pregnancy: when is leukocytapheresis appropriate? A case report and review of the literature. Transfusion, 2018, 58, 456-460.	1.6	13
78	Fat embolism syndrome due to bone marrow necrosis in patients with hemoglobinopathies: A lifeâ€threatening complication mimicking thrombotic thrombocytopenic purpura. American Journal of Hematology, 2019, 94, E64-E66.	4.1	13
79	Etiology of Pulmonary Thromboembolism in the Absence of Commonly Recognized Risk Factors. American Journal of Forensic Medicine and Pathology, 2003, 24, 329-333.	0.8	12
80	Teaching Medical Students Basic Principles of Laboratory Medicine. Clinics in Laboratory Medicine, 2007, 27, 411-424.	1.4	12
81	The Association Between ABO Blood Type and Mortality Among Severely Injured Trauma Patients. Shock, 2020, 54, 205-208.	2.1	12
82	Therapeutic plasma exchange rapidly improves cardiac allograft function in patients with presumed antibodyâ€mediated rejection. Journal of Clinical Apheresis, 2014, 29, 316-321.	1.3	11
83	Ficin-Treated Red Cells Help Identify Clinically Significant Alloantibodies Masked as Reactions of Undetermined Specificity in Gel Microtubes. Laboratory Medicine, 2017, 48, 24-28.	1.2	11
84	Opportunities to Enhance Laboratory Professionals' Role On the Diagnostic Team. Laboratory Medicine, 2017, 48, 97-103.	1.2	11
85	Civilian walking blood bank emergency preparedness plan. Transfusion, 2021, 61, S313-S325.	1.6	11
86	Histologic examination of bone marrow core biopsy specimens has limited value in the diagnosis of mycobacterial and fungal infections in patients with the acquired immunodeficiency syndrome. Annals of Diagnostic Pathology, 2000, 4, 1-6.	1.3	10
87	Clinical Pathology Consultation Improves Coagulation Factor Utilization in Hospitalized Adults. American Journal of Clinical Pathology, 2003, 120, 938-943.	0.7	10
88	Out with the bad and in with the good; red cell exchange, white cell reduction, and platelet reduction. Journal of Clinical Apheresis, 2014, 29, 220-227.	1.3	10
89	Establishing an institutional therapeutic apheresis registry. Journal of Clinical Apheresis, 2016, 31, 516-522.	1.3	10
90	Hospitalâ€acquired anemia due to diagnostic and therapyâ€related blood loss in inpatients with myasthenia gravis receiving therapeutic plasma exchange. Journal of Clinical Apheresis, 2018, 33, 14-20.	1.3	10

#	Article	IF	CITATIONS
91	Mobilization of Hematopoietic Progenitor Cells for Autologous Transplantation Using Pegfilgrastim and Plerixafor: Efficacy and Cost Implications. Biology of Blood and Marrow Transplantation, 2019, 25, 233-238.	2.0	10
92	Initial experimental experience of tripleâ€knockout pig red blood cells as potential sources for transfusion in alloimmunized patients with sickle cell disease. Transfusion, 2021, 61, 3104-3118.	1.6	10
93	The Effect of Lupus Anticoagulant in the Second-Generation Assay for Activated Protein C Resistance. American Journal of Clinical Pathology, 2003, 119, 66-71.	0.7	9
94	Screening With the Activated Protein C Resistance Assay Yields Significant Savings in a Patient Population With Low Prevalence of Factor V Leiden. American Journal of Clinical Pathology, 2008, 129, 494-499.	0.7	9
95	The thrombotic microangiopathy Registry of North America: A United States multiâ€institutional <scp>TMA</scp> network. Journal of Clinical Apheresis, 2016, 31, 448-453.	1.3	9
96	Novel <i>ADAMTS13</i> mutations in an obstetric patient with Upshawâ€Schulman syndrome. Journal of Clinical Apheresis, 2013, 28, 311-316.	1.3	8
97	Apheresis research–more abstracts should be published as full manuscripts to provide more evidence for clinical practice guidelines. Journal of Clinical Apheresis, 2016, 31, 353-358.	1.3	8
98	Questioning the association between ABO type and outcomes in patients with COVID-19. Annals of Hematology, 2020, 100, 3081-3082.	1.8	8
99	Successful pulmonary thromboendarterectomy in a patient with sickle cell disease treated with a single preoperative red blood cell exchange. Transfusion, 2014, 54, 1901-1902.	1.6	7
100	Use of hydroxyethyl starch in leukocytapheresis procedures does not increase renal toxicity. Transfusion, 2016, 56, 2848-2856.	1.6	7
101	Inside Out: Bone Marrow Necrosis and Fat Embolism Complicating Sickle- $\hat{I}^2$ + Thalassemia. American Journal of Medicine, 2016, 129, e321-e324.	1.5	7
102	New subcutaneous PowerFlow port results in cost and timeâ€savings in a busy outpatient apheresis clinic. Journal of Clinical Apheresis, 2018, 34, 482-486.	1.3	7
103	Thrombotic thrombocytopenic purpura does not show seasonal variation in <scp>A</scp> labama. Transfusion, 2013, 53, 1864-1865.	1.6	5
104	Periprocedural Management of Patients on Anticoagulants. Clinics in Laboratory Medicine, 2014, 34, 595-611.	1.4	5
105	Rhesus Immune Globulin Dosing in the Obesity Epidemic Era. Archives of Pathology and Laboratory Medicine, 2015, 139, 1084-1084.	2.5	5
106	Society for the Advancement of Patient Blood Management and Anesthesia & Society for the Advancement of Patient Blood Management and Analgesia & Analgesia; A New Collaboration and Home for Blood Management Research. Anesthesia and Analgesia, 2016, 123, 816-817.	2.2	5
107	Therapeutic plasma exchange For Hashimoto's encephalopathy. Journal of Clinical Apheresis, 2018, 33, 444-446.	1.3	5
108	Validation and cost-effectiveness of an in-house dithiothreitol (DTT) treatment protocol for daratumumab patients in a large tertiary care hospital provides gateway for implementation in smaller community hospitals. Transfusion and Apheresis Science, 2019, 58, 152-155.	1.0	5

#	Article	IF	Citations
109	Damage to red blood cells during whole blood storage. Journal of Trauma and Acute Care Surgery, 2020, 89, 344-350.	2.1	5
110	From Activated Partial Thromboplastin Time to Antifactor Xa and Back Again. American Journal of Clinical Pathology, 2022, 157, 321-327.	0.7	5
111	When to suspect hypercoagulability and how to investigate it. Annals of Diagnostic Pathology, 2001, 5, 177-183.	1.3	4
112	Systemic neutrophilic aggregates in transfusion-related acute lung injury. Transfusion, 2010, 50, 1427-1428.	1.6	4
113	von Willebrand Disease Laboratory Diagnosis. American Journal of Clinical Pathology, 2011, 135, 818-820.	0.7	4
114	Therapeutic plasma exchange for intractable pruritus secondary to primary sclerosing cholangitis. Journal of Clinical Apheresis, 2016, 31, 495-496.	1.3	4
115	The level of complement activation fragments is higher in red blood cell units than segments. Transfusion and Apheresis Science, 2013, 49, 692-693.	1.0	3
116	The American Society for Apheresis (ASFA) is pleased to offer a Qualification in Apheresis (QIA) in partnership with The Board of Certification (BOC) of the American Society for Clinical Pathology (ASCP) starting in January of 2016!. Transfusion and Apheresis Science, 2016, 54, 319-320.	1.0	3
117	Perception of risk in massive transfusion as it relates to fetal outcomes: A survey of surgeons and nurses at one American trauma center. Transfusion, 2021, 61, S159-S166.	1.6	3
118	The Effect of Lupus Anticoagulant in the Second-Generation Assay for Activated Protein C Resistance. American Journal of Clinical Pathology, 2003, 119, 66-71.	0.7	3
119	Thrombotic Thrombocytopenic Purpura. Pathology Patterns Reviews, 2004, 121, S89-S96.	0.4	2
120	A Neonate With Bleeding and Multiple Factor Deficiencies. Laboratory Medicine, 2006, 37, 95-97.	1.2	2
121	Blood Utilization at a Level I Trauma Center: Is this as Good as it Gets?. American Surgeon, 2009, 75, 693-698.	0.8	2
122	Primary Care Physicians and the Laboratory. American Journal of Clinical Pathology, 2014, 142, 738-740.	0.7	2
123	Do Institution-Level Blood Utilization and Blood Management Initiatives Meaningfully Impact Transfusion Practices in Cardiac Surgery?. Anesthesia and Analgesia, 2017, 125, 731-733.	2.2	2
124	A safe and effective management strategy for BCVI. Journal of Trauma and Acute Care Surgery, 2017, 82, 228.	2.1	2
125	Plasma Levels of Human Neutrophil Peptides and Complement Activation Markers in Patients with Acquired Autoimmune Thrombotic Thrombocytopenic Purpura. Blood, 2015, 126, 1147-1147.	1.4	2
126	A new "initial―case of transfusion-related acute lung injury. Blood, 2008, 111, 5257-5258.	1.4	1

#	Article	IF	Citations
127	Massive hemolysis due to thrombotic thrombocytopenic purpura in a patient with AIDS. Transfusion, 2012, 52, 1408-1409.	1.6	1
128	Therapeutic apheresis academy 2013: Beyond borders. Journal of Clinical Apheresis, 2014, 29, 189-190.	1.3	1
129	An Unusual Presentation of Thrombotic Thrombocytopenic Purpura. American Journal of Medicine, 2017, 130, e323-e326.	1.5	1
130	An Automated Method for Direct Antiglobulin Testing and the Resulting Amount of Phototherapy Used at a Large Academic Medical Center. Laboratory Medicine, 2020, 51, 50-55.	1.2	1
131	Exclusive use of PowerFlow ports may not be appropriate for all patients. Journal of Clinical Apheresis, 2020, 35, 66-68.	1.3	1
132	Clinical Pathology Consultation Improves Coagulation Factor Utilization in Hospitalized Adults. American Journal of Clinical Pathology, 2003, 120, 938-943.	0.7	1
133	Allergic reaction to psoralenâ€treated platelets: Real or coincidence?. Transfusion, 2022, 62, 716-717.	1.6	1
134	Passenger Lymphocyte Syndrome and Autoimmune Hypothyroidism Following Hematopoietic Stem Cell Transplantation. Case Reports in Immunology, 2022, 2022, 1-6.	0.4	1
135	Refractory thrombocytopenia and positive platelet crossmatches without HLA or platelet-specific antibodies. American Journal of Hematology, 2007, 82, 175-176.	4.1	0
136	An Adolescent With a History of Menorrhagia. Laboratory Medicine, 2009, 40, 271-273.	1.2	0
137	A Simple Tool to Educate Laboratory Staff About Anticoagulation. Laboratory Medicine, 2009, 40, 687-690.	1.2	0
138	49: Evaluation of Aspirin Resistance in Patients With Left Ventricular Assist Devices Using Whole Blood Platelet Aggregometry. American Journal of Clinical Pathology, 2015, 143, A025-A025.	0.7	0
139	Therapeutic Apheresis for Hematologic Emergencies. , 2018, , 341-361.		0
140	Patient Blood Management. , 2018, , 201-218.		0
141	Solving the calcium gluconate shortage in realâ€time: Mistakes made and lessons learned. Journal of Clinical Apheresis, 2019, 34, 490-494.	1.3	0
142	Adaptable stewardship during a pandemic: a multifaceted approach to sustaining the blood supply for individuals with sickle cell disease. International Journal of Laboratory Hematology, 2021, 43, O168-O170.	1.3	0
143	Optimizing factor VIII dosing in obese individuals with haemophilia A. Blood Coagulation and Fibrinolysis, 2021, Publish Ahead of Print, 528-530.	1.0	0
144	Correlation of Direct Antiglobulin Test Strength in Umbilical Cord Blood and Hyperbilirubinemia in ABO Incompatible Neonates with Two Methods. Blood, 2018, 132, 5072-5072.	1.4	0

#	Article	IF	CITATIONS
145	Longitudinal Assessment of Plasma ADAMTS13 Biomarkers Helps Predict Recurrence of Immune Thrombotic Thrombocytopenic Purpura. Blood, 2019, 134, 2456-2456.	1.4	O
146	Exome Sequencing Identifies Glycosylation Defects As a Probable Cause of Immune Thrombotic Thrombocytopenic Purpura. Blood, 2019, 134, 217-217.	1.4	0
147	A Road Paved with Good Intentions: A Platelet Count-Based Alert to Facilitate Diagnosis of Heparin-Induced Thrombocytopenia. Blood, 2021, 138, 756-756.	1.4	O
148	Caring for Patients with Sickle Cell Disease during a Pandemic: Continuing to Provide Automated Red Blood Cell Exchange Transfusions in Difficult Times. Blood, 2020, 136, 25-26.	1.4	0
149	Testing for genetic predisposition to venous thrombosis. Medical Laboratory Observer, 2002, 34, 8-13; quiz 20-1.	0.1	O
150	Treatment of single factor deficiencies: a case study approach. Clinical Laboratory Science: Journal of the American Society for Medical Technology, 2003, 16, 120-2.	0.1	0